Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
DALLAS, Sept. 26, 2017 -- TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, today announced that Edward Parent has been appointed Director, Quality Assurance to guide clinical application and commercial scale-up of its core technology. Parent brings over 35 years of experience working in a broad range of FDA regulated environments and guiding compliance with GMP requirements and various quality management systems.
Parent’s diverse career has included positions with start-up companies like Biomatrix Inc. and Hylamed Inc / LuroMed LLC and large corporations such as Johnson & Johnson and Genzyme Biosurgery in roles including Director of Technical Operations, Principal Scientist, and Quality Engineer. He has been responsible for advancing multiple early stage products from concept to clinical trial and commercialization. Prior to joining TissueGen, Ed most recently served as a scientist at Evonik Industries, where he advised and implemented technology transfer, scale up, and new product development of biodegradable polymers.
“We see a tremendous opportunity for ELUTE fiber to redefine the way drug delivery, tissue engineering and nerve regeneration are approached. The combination of biotech, medical device and pharmaceutical industry expertise that Mr. Parent brings to TissueGen will accelerate our path towards clinical application and scale up commercialization of ELUTE fiber-based products,” said Christopher Knowles, President and CEO of TissueGen.
TissueGen’s ELUTE fiber can directly replace standard fibers in biodegradable medical textiles and may significantly improve clinical outcomes by delivering therapeutic agents directly at the surgical site. Through localized delivery of drugs at the site of implantation, ELUTE fibers may orchestrate the body’s healing and regenerative processes.
“ELUTE fiber has the potential to play a pivotal role in the next-generation of medical devices and I am eager to apply the skills I’ve honed throughout my career to guide the company towards clinical application and large-scale commercialization.” said Parent.
Parent is a member of the Society for Biomaterials, Controlled Release Society and American Society for Quality. He is also a published author and holds four patents.
About TissueGen
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.
For more information, please visit www.tissuegen.com.
For more information contact: Jordan Bouclin SVM Public Relations 401-490-9700 [email protected]
